416 related articles for article (PubMed ID: 29455667)
1. Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products.
Siveen KS; Prabhu KS; Achkar IW; Kuttikrishnan S; Shyam S; Khan AQ; Merhi M; Dermime S; Uddin S
Mol Cancer; 2018 Feb; 17(1):31. PubMed ID: 29455667
[TBL] [Abstract][Full Text] [Related]
2. Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells.
Gocek E; Moulas AN; Studzinski GP
Crit Rev Clin Lab Sci; 2014 Jun; 51(3):125-37. PubMed ID: 24446827
[TBL] [Abstract][Full Text] [Related]
3. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
Hojjat-Farsangi M
J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367
[TBL] [Abstract][Full Text] [Related]
4. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.
Chase A; Cross NC
Clin Sci (Lond); 2006 Oct; 111(4):233-49. PubMed ID: 16961463
[TBL] [Abstract][Full Text] [Related]
5. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
Zhu N; Xiao H; Wang LM; Fu S; Zhao C; Huang H
Future Oncol; 2015; 11(4):659-73. PubMed ID: 25686120
[TBL] [Abstract][Full Text] [Related]
6. JAK/STAT signal transduction: regulators and implication in hematological malignancies.
Valentino L; Pierre J
Biochem Pharmacol; 2006 Mar; 71(6):713-21. PubMed ID: 16426581
[TBL] [Abstract][Full Text] [Related]
7. Local substrates of non-receptor tyrosine kinases at synaptic sites in neurons.
Mao LM; Geosling R; Penman B; Wang JQ
Sheng Li Xue Bao; 2017 Oct; 69(5):657-665. PubMed ID: 29063113
[TBL] [Abstract][Full Text] [Related]
8. Activation of the focal adhesion kinase signaling pathway by structural alterations in the carboxyl-terminal region of c-Crk II.
Zvara A; Fajardo JE; Escalante M; Cotton G; Muir T; Kirsch KH; Birge RB
Oncogene; 2001 Feb; 20(8):951-61. PubMed ID: 11314030
[TBL] [Abstract][Full Text] [Related]
9. After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies.
Wadleigh M; DeAngelo DJ; Griffin JD; Stone RM
Blood; 2005 Jan; 105(1):22-30. PubMed ID: 15358622
[TBL] [Abstract][Full Text] [Related]
10. Invadopodia, a Kingdom of Non-Receptor Tyrosine Kinases.
Saha T; Gil-Henn H
Cells; 2021 Aug; 10(8):. PubMed ID: 34440806
[TBL] [Abstract][Full Text] [Related]
11. [Abnormal activation of tyrosine kinases and its role in the pathogenesis of hematological malignancies - review].
Sun XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun; 15(3):657-61. PubMed ID: 17605888
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease.
Scheijen B; Griffin JD
Oncogene; 2002 May; 21(21):3314-33. PubMed ID: 12032772
[TBL] [Abstract][Full Text] [Related]
13. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
14. Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders.
Nelson KN; Peiris MN; Meyer AN; Siari A; Donoghue DJ
Trends Mol Med; 2017 Jan; 23(1):59-79. PubMed ID: 27988109
[TBL] [Abstract][Full Text] [Related]
15. Kinases as drug discovery targets in hematologic malignancies.
Hannah AL
Curr Mol Med; 2005 Nov; 5(7):625-42. PubMed ID: 16305489
[TBL] [Abstract][Full Text] [Related]
16. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Schenone S; Brullo C; Musumeci F; Botta M
Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
[TBL] [Abstract][Full Text] [Related]
17. Non-receptor tyrosine kinase signaling in autoimmunity and therapeutic implications.
Solouki S; August A; Huang W
Pharmacol Ther; 2019 Sep; 201():39-50. PubMed ID: 31082431
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine phosphorylation of glutamate receptors by non-receptor tyrosine kinases: roles in depression-like behavior.
Mao LM; Wang JQ
Neurotransmitter (Houst); 2016; 3():. PubMed ID: 26942227
[TBL] [Abstract][Full Text] [Related]
19. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies.
Matsumura I; Mizuki M; Kanakura Y
Cancer Sci; 2008 Mar; 99(3):479-85. PubMed ID: 18177485
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
